In this retrospective cohort study, compared to basal insulin, T2DM patients with high CVD risk who were treated with liraglutide demonstrated a lower risk of a composite CVD outcome, stroke, and all-cause mortality. The gene discussed is INS; the disease is type 2 diabetes mellitus.